Strategies for Synthesizing and Enhancing the Immune Response of Cancer Vaccines Based on MUC1 Glycopeptide Antigens.

Yin, Lixin; Zhou, Yang; Hong, Sheng; Ding, Feiqing; Cai, Hui

Yin, Lixin; Zhou, Yang; Hong, Sheng; Ding, Feiqing; Cai, Hui.

Afiliação

Yin L; School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-sen University, 66 Gongchang Lu, Guangming District, Shenzhen, 518107, China.
Zhou Y; School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-sen University, 66 Gongchang Lu, Guangming District, Shenzhen, 518107, China.
Hong S; School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-sen University, 66 Gongchang Lu, Guangming District, Shenzhen, 518107, China.
Ding F; School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-sen University, 66 Gongchang Lu, Guangming District, Shenzhen, 518107, China.
Cai H; School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-sen University, 66 Gongchang Lu, Guangming District, Shenzhen, 518107, China.

Chembiochem ; 24(10): e202200805, 2023 05 16.

Article em En | MEDLINE | ID: mdl-36825431

Assuntos

Vacinas Anticâncer; Neoplasias; Humanos; Mucina-1; Glicopeptídeos; Neoplasias/tratamento farmacológico; Imunidade

Palavras-chave

Glycopeptide synthesis; MUC1; cancer vaccine; multicomponent; multivalent

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas Anticâncer / Neoplasias Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas Anticâncer / Neoplasias Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article